[1] Trouilloud I,Dubreuil O,Boussaha T,et al.Medical treatment pancreatic cancer:new hopes after 10 years of gemcitabine[J].Clin Res Hepatol Gastroenterol,2011,35(5):364-374.
[2] ShevchenkoI,Karakhanova S, Soltek S,et al.Low-dose gemcetabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].Int J Cancer,2013,133(1):98-107.
[3] Burris HA,Moore MJ,Andersen J,et al.Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
[4] Hiraoka N,Onozato K,Kosuge T,et al.Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions[J].Clin Cancer Res,2006,12:5423-5434.
[5] Ikemoton T,Yamaguchi T,Morine Y,et al.Clinical roles of increased populations of Foxp3+ CD4+ T cells in peripheral blood from advanced pancreatic cancer patients[J].Pancreas,2006,33:386-390.
[6] Shindo Y, Hazama S, Maeda Y,et al.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcetabine for unresectable pancreatic cancer[J].J Translat Med,2014,12:175.
[7] Gabitass RF,Annels NE,Stocken DD,et al.Elevated myeloid-derived suppressor cells in pancreatic,esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13[J].Cancer Immunol Immunother,2011,60:1419-1430.
[8] Ghansah T, Vohra N, Kinney K,et al.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J].Cancer Immunol Immunother,2013,62:1083-1091.
[9] 高 强,邱双健,樊 嘉.CD4+ CD25+ FOXP3+调节性T细胞在肿瘤免疫逃逸中的作用研究进展[J].中国癌症杂志,2007,17(8):657-662.
[10] 卢晓婷,刘俊田. CD4+ CD25+调节性T细胞在肿瘤免疫及化疗方面的研究进展[J].中国肿瘤临床,2008,35(11):656-660.
[11] Homma Y,Tangiguchi K,Nakazawa M,et al.Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer[J].Clini Translat Oncol,2014,16:330-335.
[12] Bunt SK,Mohr AM,Bailey JM,et al.Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T populations in pancreatic cancer[J].Cancer Immunol Immunother,2013,62:225-236.